PDCD1 and neoplasm: Firstly, there is a need to explore the most selective and active cMET inhibitor with less off-target toxicities and high anti-tumor activity and then to evaluate the best ICI agent (anti-PD1 or/and anti-LAG3) to combine for mUM treatment.